Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lung Neoplasms | 75 | 2022 | 13102 | 1.600 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 42 | 2018 | 5221 | 1.310 |
Why?
|
Movement | 12 | 2016 | 1471 | 1.170 |
Why?
|
Fluorodeoxyglucose F18 | 11 | 2018 | 2016 | 1.010 |
Why?
|
Esophageal Neoplasms | 16 | 2016 | 1583 | 0.960 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 14 | 2018 | 1624 | 0.950 |
Why?
|
Carcinoma, Small Cell | 16 | 2003 | 420 | 0.940 |
Why?
|
Respiration | 8 | 2013 | 1653 | 0.780 |
Why?
|
Small Cell Lung Carcinoma | 3 | 2014 | 388 | 0.710 |
Why?
|
Radiation Pneumonitis | 5 | 2018 | 104 | 0.650 |
Why?
|
Radiotherapy Dosage | 22 | 2017 | 2879 | 0.600 |
Why?
|
Radiopharmaceuticals | 5 | 2014 | 2645 | 0.560 |
Why?
|
Positron-Emission Tomography | 8 | 2018 | 6234 | 0.530 |
Why?
|
Neoadjuvant Therapy | 11 | 2016 | 2728 | 0.490 |
Why?
|
Radiotherapy, Conformal | 5 | 2014 | 548 | 0.460 |
Why?
|
Tomography, X-Ray Computed | 16 | 2022 | 20129 | 0.410 |
Why?
|
Fanconi Anemia Complementation Group D2 Protein | 1 | 2011 | 148 | 0.380 |
Why?
|
Thymus Neoplasms | 7 | 2013 | 268 | 0.380 |
Why?
|
Combined Modality Therapy | 42 | 2011 | 8642 | 0.360 |
Why?
|
Neoplasm Recurrence, Local | 8 | 2018 | 9239 | 0.350 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 24 | 2016 | 11524 | 0.350 |
Why?
|
Radiation Injuries | 7 | 2018 | 1180 | 0.340 |
Why?
|
Thymoma | 6 | 2013 | 186 | 0.340 |
Why?
|
Radiotherapy | 10 | 2018 | 1533 | 0.290 |
Why?
|
Cisplatin | 19 | 2016 | 1662 | 0.270 |
Why?
|
Radiotherapy, Intensity-Modulated | 4 | 2018 | 806 | 0.250 |
Why?
|
Neoplasm Staging | 23 | 2018 | 11031 | 0.240 |
Why?
|
Amifostine | 1 | 2003 | 41 | 0.240 |
Why?
|
Glucose | 6 | 2014 | 4397 | 0.240 |
Why?
|
Radiation-Protective Agents | 1 | 2003 | 90 | 0.230 |
Why?
|
Lung | 8 | 2018 | 9856 | 0.210 |
Why?
|
DNA Repair | 1 | 2011 | 2046 | 0.210 |
Why?
|
Respiratory Mechanics | 1 | 2006 | 686 | 0.210 |
Why?
|
Paclitaxel | 5 | 2018 | 1708 | 0.200 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2008 | 1184 | 0.190 |
Why?
|
Aged | 59 | 2022 | 163280 | 0.190 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2011 | 2916 | 0.190 |
Why?
|
Adenocarcinoma | 12 | 2011 | 6364 | 0.180 |
Why?
|
Aged, 80 and over | 26 | 2018 | 57776 | 0.170 |
Why?
|
Carcinoma, Bronchogenic | 3 | 1986 | 87 | 0.170 |
Why?
|
Carcinoma, Squamous Cell | 12 | 2011 | 4034 | 0.170 |
Why?
|
Imaging, Three-Dimensional | 3 | 2008 | 4042 | 0.160 |
Why?
|
Nuclear Proteins | 2 | 2011 | 5853 | 0.150 |
Why?
|
Middle Aged | 60 | 2018 | 213383 | 0.150 |
Why?
|
Tomography, Emission-Computed | 7 | 2004 | 1144 | 0.150 |
Why?
|
Fluorouracil | 11 | 2006 | 1619 | 0.140 |
Why?
|
Carboplatin | 3 | 2018 | 801 | 0.140 |
Why?
|
Lymph Nodes | 1 | 2007 | 3474 | 0.140 |
Why?
|
Male | 64 | 2018 | 350118 | 0.140 |
Why?
|
Survival Rate | 14 | 2017 | 12788 | 0.130 |
Why?
|
Radiosurgery | 2 | 2018 | 1329 | 0.130 |
Why?
|
Humans | 99 | 2022 | 744343 | 0.130 |
Why?
|
Female | 66 | 2018 | 380194 | 0.130 |
Why?
|
Tumor Burden | 5 | 2016 | 1915 | 0.130 |
Why?
|
Thymectomy | 2 | 2013 | 191 | 0.130 |
Why?
|
Probability | 3 | 2013 | 2505 | 0.120 |
Why?
|
Sensitivity and Specificity | 6 | 2014 | 14722 | 0.120 |
Why?
|
Pneumonectomy | 4 | 2009 | 1094 | 0.120 |
Why?
|
Cyclooxygenase 2 Inhibitors | 1 | 2016 | 320 | 0.120 |
Why?
|
Spinal Cord Neoplasms | 2 | 1987 | 281 | 0.120 |
Why?
|
Respiratory Function Tests | 4 | 1994 | 1616 | 0.110 |
Why?
|
Lung Injury | 1 | 2018 | 436 | 0.110 |
Why?
|
Esophagitis | 3 | 2003 | 152 | 0.100 |
Why?
|
Lymphatic Metastasis | 4 | 2010 | 2924 | 0.100 |
Why?
|
Lung Diseases | 2 | 1994 | 1886 | 0.100 |
Why?
|
Analysis of Variance | 2 | 2011 | 6365 | 0.090 |
Why?
|
Etoposide | 5 | 2013 | 641 | 0.090 |
Why?
|
Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2011 | 284 | 0.090 |
Why?
|
Adult | 37 | 2018 | 214055 | 0.090 |
Why?
|
Deoxyglucose | 3 | 1996 | 337 | 0.090 |
Why?
|
Drug Administration Schedule | 5 | 2016 | 4933 | 0.090 |
Why?
|
Smoking Cessation | 1 | 2022 | 2071 | 0.090 |
Why?
|
Protein Array Analysis | 1 | 2011 | 411 | 0.090 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 2011 | 440 | 0.090 |
Why?
|
Lymphatic Irradiation | 1 | 2009 | 103 | 0.080 |
Why?
|
Feasibility Studies | 6 | 2018 | 5078 | 0.080 |
Why?
|
ras Proteins | 1 | 2014 | 1060 | 0.080 |
Why?
|
Preoperative Care | 4 | 2013 | 2250 | 0.080 |
Why?
|
Prospective Studies | 10 | 2017 | 53288 | 0.080 |
Why?
|
Carcinoma, Large Cell | 2 | 2007 | 113 | 0.080 |
Why?
|
Carcinoma | 3 | 2013 | 2375 | 0.080 |
Why?
|
Brain Neoplasms | 5 | 2014 | 8863 | 0.080 |
Why?
|
Creatine Kinase, MB Form | 1 | 2008 | 214 | 0.080 |
Why?
|
Fluorine Radioisotopes | 3 | 1996 | 442 | 0.080 |
Why?
|
Artifacts | 2 | 2008 | 1904 | 0.070 |
Why?
|
Consensus | 1 | 2016 | 2959 | 0.070 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2014 | 1660 | 0.070 |
Why?
|
Treatment Outcome | 17 | 2014 | 63114 | 0.070 |
Why?
|
Mediastinum | 1 | 2007 | 267 | 0.070 |
Why?
|
Disease-Free Survival | 4 | 2016 | 6895 | 0.070 |
Why?
|
Monte Carlo Method | 2 | 2013 | 1254 | 0.070 |
Why?
|
Retrospective Studies | 16 | 2018 | 77449 | 0.070 |
Why?
|
Radiometry | 2 | 2018 | 800 | 0.070 |
Why?
|
Point Mutation | 1 | 2011 | 1623 | 0.070 |
Why?
|
Scattering, Radiation | 2 | 2018 | 498 | 0.070 |
Why?
|
Chemotherapy, Adjuvant | 6 | 2008 | 3479 | 0.070 |
Why?
|
Dose-Response Relationship, Radiation | 2 | 2002 | 876 | 0.070 |
Why?
|
Neoplasm Invasiveness | 3 | 2013 | 3616 | 0.060 |
Why?
|
Pericardial Effusion | 1 | 1987 | 247 | 0.060 |
Why?
|
Dura Mater | 1 | 1987 | 291 | 0.060 |
Why?
|
Esophagogastric Junction | 3 | 2016 | 313 | 0.060 |
Why?
|
Risk | 5 | 2018 | 9687 | 0.060 |
Why?
|
Prognosis | 10 | 2011 | 29063 | 0.060 |
Why?
|
Radiotherapy, High-Energy | 2 | 1981 | 228 | 0.060 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2008 | 1770 | 0.060 |
Why?
|
Neoplasm Proteins | 2 | 2011 | 3703 | 0.060 |
Why?
|
Troponin T | 1 | 2008 | 754 | 0.060 |
Why?
|
Regression Analysis | 1 | 2013 | 6459 | 0.060 |
Why?
|
Kaplan-Meier Estimate | 4 | 2014 | 6538 | 0.050 |
Why?
|
Proto-Oncogene Proteins | 1 | 2014 | 4554 | 0.050 |
Why?
|
Reference Values | 1 | 2009 | 4982 | 0.050 |
Why?
|
Treatment Failure | 3 | 2003 | 2618 | 0.050 |
Why?
|
Smoking | 1 | 2018 | 8987 | 0.050 |
Why?
|
Camptothecin | 2 | 2016 | 576 | 0.050 |
Why?
|
Organs at Risk | 2 | 2016 | 346 | 0.050 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2011 | 2915 | 0.050 |
Why?
|
Genotype | 2 | 2014 | 12951 | 0.050 |
Why?
|
Radiation Dosage | 3 | 2018 | 1928 | 0.050 |
Why?
|
Lymphatic System | 1 | 2002 | 253 | 0.050 |
Why?
|
Follow-Up Studies | 10 | 2017 | 39050 | 0.050 |
Why?
|
Bayes Theorem | 2 | 2018 | 2309 | 0.040 |
Why?
|
Fibrosarcoma | 1 | 2002 | 348 | 0.040 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2008 | 1573 | 0.040 |
Why?
|
Reproducibility of Results | 4 | 2018 | 19905 | 0.040 |
Why?
|
Clinical Trials as Topic | 5 | 2016 | 7913 | 0.040 |
Why?
|
Predictive Value of Tests | 2 | 2001 | 15076 | 0.040 |
Why?
|
Melanoma, Experimental | 1 | 2002 | 561 | 0.040 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2003 | 1375 | 0.040 |
Why?
|
Meningeal Neoplasms | 1 | 1987 | 1241 | 0.040 |
Why?
|
Cranial Fossa, Posterior | 2 | 1987 | 139 | 0.030 |
Why?
|
Survival Analysis | 6 | 2008 | 10252 | 0.030 |
Why?
|
Anorexia | 1 | 2016 | 161 | 0.030 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2013 | 8949 | 0.030 |
Why?
|
Peptide Fragments | 1 | 2008 | 5097 | 0.030 |
Why?
|
Proliferating Cell Nuclear Antigen | 1 | 1996 | 285 | 0.030 |
Why?
|
Photons | 1 | 2018 | 588 | 0.030 |
Why?
|
Membrane Proteins | 1 | 2011 | 7880 | 0.030 |
Why?
|
Time Factors | 9 | 2013 | 40075 | 0.030 |
Why?
|
DNA-Binding Proteins | 1 | 2011 | 9648 | 0.030 |
Why?
|
Ventilation-Perfusion Ratio | 1 | 1994 | 116 | 0.030 |
Why?
|
Postoperative Period | 3 | 1991 | 1842 | 0.030 |
Why?
|
Nausea | 1 | 2016 | 673 | 0.030 |
Why?
|
Protons | 1 | 2018 | 1127 | 0.030 |
Why?
|
Computer Simulation | 1 | 2006 | 6196 | 0.030 |
Why?
|
Antineoplastic Agents | 5 | 2003 | 13695 | 0.030 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2011 | 15519 | 0.030 |
Why?
|
Magnetic Resonance Angiography | 1 | 1999 | 1442 | 0.030 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2005 | 3327 | 0.030 |
Why?
|
Vinblastine | 3 | 2002 | 502 | 0.020 |
Why?
|
Radiography | 3 | 2009 | 7023 | 0.020 |
Why?
|
Relative Biological Effectiveness | 1 | 2013 | 323 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2011 | 9959 | 0.020 |
Why?
|
Pleural Neoplasms | 1 | 1996 | 607 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2011 | 8428 | 0.020 |
Why?
|
Deglutition Disorders | 1 | 2016 | 605 | 0.020 |
Why?
|
Proportional Hazards Models | 2 | 2018 | 12354 | 0.020 |
Why?
|
North America | 1 | 2013 | 1249 | 0.020 |
Why?
|
Lymphoma | 1 | 1979 | 1877 | 0.020 |
Why?
|
Remission Induction | 2 | 2008 | 2386 | 0.020 |
Why?
|
Mesothelioma | 1 | 1996 | 818 | 0.020 |
Why?
|
Liver Neoplasms | 1 | 2005 | 4253 | 0.020 |
Why?
|
Safety | 1 | 1994 | 1186 | 0.020 |
Why?
|
Forced Expiratory Volume | 1 | 1994 | 1743 | 0.020 |
Why?
|
Blood Gas Analysis | 1 | 1990 | 383 | 0.020 |
Why?
|
Administration, Oral | 1 | 2016 | 3913 | 0.020 |
Why?
|
Data Interpretation, Statistical | 1 | 2018 | 2716 | 0.020 |
Why?
|
Endpoint Determination | 1 | 2011 | 601 | 0.020 |
Why?
|
Young Adult | 4 | 2018 | 56430 | 0.020 |
Why?
|
Early Detection of Cancer | 1 | 2022 | 3086 | 0.020 |
Why?
|
Linear Models | 1 | 2018 | 5952 | 0.020 |
Why?
|
Multivariate Analysis | 2 | 2011 | 12245 | 0.020 |
Why?
|
Esophagus | 2 | 2010 | 1019 | 0.020 |
Why?
|
Actuarial Analysis | 1 | 1987 | 378 | 0.020 |
Why?
|
Exhalation | 1 | 2007 | 167 | 0.020 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 1692 | 0.020 |
Why?
|
Mediastinal Diseases | 1 | 2007 | 89 | 0.020 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2011 | 602 | 0.020 |
Why?
|
Risk Factors | 5 | 2018 | 72290 | 0.020 |
Why?
|
Algorithms | 2 | 2005 | 13881 | 0.020 |
Why?
|
Diagnostic Tests, Routine | 1 | 2011 | 783 | 0.020 |
Why?
|
Brain Ischemia | 1 | 1999 | 3265 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2010 | 2886 | 0.020 |
Why?
|
Medicare | 1 | 2022 | 6566 | 0.010 |
Why?
|
Stomach Neoplasms | 1 | 2013 | 1333 | 0.010 |
Why?
|
Pilot Projects | 2 | 2013 | 8324 | 0.010 |
Why?
|
Water | 1 | 2009 | 1395 | 0.010 |
Why?
|
ROC Curve | 1 | 2011 | 3527 | 0.010 |
Why?
|
Confidence Intervals | 1 | 2008 | 2971 | 0.010 |
Why?
|
Vascular Endothelial Growth Factor C | 1 | 2002 | 126 | 0.010 |
Why?
|
Lymphography | 1 | 2002 | 201 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 2 | 1999 | 35421 | 0.010 |
Why?
|
Radioisotope Teletherapy | 1 | 1980 | 18 | 0.010 |
Why?
|
Cough | 1 | 2004 | 555 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2022 | 25043 | 0.010 |
Why?
|
Mice, Inbred C3H | 1 | 2002 | 964 | 0.010 |
Why?
|
Maximum Tolerated Dose | 1 | 2003 | 892 | 0.010 |
Why?
|
Immunoenzyme Techniques | 2 | 1996 | 1799 | 0.010 |
Why?
|
Diagnosis, Differential | 2 | 2007 | 12959 | 0.010 |
Why?
|
Incidence | 1 | 2018 | 20947 | 0.010 |
Why?
|
Extracellular Space | 1 | 2002 | 594 | 0.010 |
Why?
|
Molecular Targeted Therapy | 1 | 2011 | 2727 | 0.010 |
Why?
|
Radiographic Image Enhancement | 1 | 2005 | 885 | 0.010 |
Why?
|
Taxoids | 1 | 2003 | 666 | 0.010 |
Why?
|
Technetium Tc 99m Exametazime | 1 | 1999 | 68 | 0.010 |
Why?
|
Endothelial Growth Factors | 1 | 2002 | 694 | 0.010 |
Why?
|
Postoperative Care | 1 | 1986 | 1486 | 0.010 |
Why?
|
Vesicular Transport Proteins | 1 | 2002 | 377 | 0.010 |
Why?
|
Peptides | 1 | 1991 | 4409 | 0.010 |
Why?
|
Cerebral Arterial Diseases | 1 | 1999 | 82 | 0.010 |
Why?
|
Pressure | 1 | 2002 | 1203 | 0.010 |
Why?
|
Remission, Spontaneous | 1 | 1979 | 382 | 0.010 |
Why?
|
Neoplasm Transplantation | 1 | 2002 | 2085 | 0.010 |
Why?
|
Antigens, Surface | 1 | 2002 | 1663 | 0.010 |
Why?
|
Blood Volume | 1 | 1999 | 565 | 0.010 |
Why?
|
Neoplasm Metastasis | 1 | 1988 | 4851 | 0.010 |
Why?
|
Mutation | 2 | 2011 | 29786 | 0.010 |
Why?
|
Microscopy | 1 | 2002 | 903 | 0.010 |
Why?
|
Odds Ratio | 1 | 2009 | 9849 | 0.010 |
Why?
|
Membrane Transport Proteins | 1 | 2002 | 1028 | 0.010 |
Why?
|
Animals | 3 | 2003 | 168757 | 0.010 |
Why?
|
Hospital Mortality | 1 | 2009 | 5317 | 0.010 |
Why?
|
Mice, Nude | 1 | 2002 | 3689 | 0.010 |
Why?
|
Sarcoma | 1 | 1987 | 1897 | 0.010 |
Why?
|
Biopsy | 1 | 2007 | 6756 | 0.010 |
Why?
|
Colonic Neoplasms | 1 | 1987 | 2541 | 0.010 |
Why?
|
Arterial Occlusive Diseases | 1 | 1999 | 793 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 2002 | 6314 | 0.010 |
Why?
|
Glycoproteins | 1 | 2002 | 2263 | 0.010 |
Why?
|
United States | 1 | 2022 | 69872 | 0.010 |
Why?
|
Cerebral Infarction | 1 | 1999 | 1011 | 0.010 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 1 | 1999 | 1107 | 0.010 |
Why?
|
Ki-67 Antigen | 1 | 1996 | 644 | 0.010 |
Why?
|
Patient Care Planning | 1 | 1999 | 921 | 0.010 |
Why?
|
Neoplasms | 1 | 2002 | 21683 | 0.010 |
Why?
|
Breast Neoplasms | 2 | 1993 | 20822 | 0.010 |
Why?
|
Blood Vessels | 1 | 1998 | 1125 | 0.010 |
Why?
|
Gastrin-Releasing Peptide | 1 | 1991 | 38 | 0.010 |
Why?
|
Cerebrovascular Disorders | 1 | 1999 | 1504 | 0.010 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 1979 | 1381 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2013 | 15295 | 0.010 |
Why?
|
Cranial Irradiation | 1 | 1994 | 401 | 0.010 |
Why?
|
Thrombocytopenia | 1 | 1979 | 1179 | 0.010 |
Why?
|
Drug Evaluation | 1 | 1992 | 647 | 0.010 |
Why?
|
Blood Glucose | 2 | 1996 | 6256 | 0.010 |
Why?
|
Forecasting | 1 | 2000 | 2951 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2003 | 10943 | 0.010 |
Why?
|
Carcinoid Tumor | 1 | 1991 | 235 | 0.010 |
Why?
|
Cerebrovascular Circulation | 1 | 1999 | 2731 | 0.010 |
Why?
|
RNA, Neoplasm | 1 | 1991 | 769 | 0.010 |
Why?
|
Acute Disease | 1 | 1999 | 7149 | 0.000 |
Why?
|
Immunohistochemistry | 1 | 2002 | 11366 | 0.000 |
Why?
|
Cohort Studies | 1 | 2011 | 40561 | 0.000 |
Why?
|
Image Enhancement | 1 | 1999 | 2921 | 0.000 |
Why?
|
Infusions, Intravenous | 1 | 1993 | 2274 | 0.000 |
Why?
|
In Situ Hybridization | 1 | 1991 | 1950 | 0.000 |
Why?
|
Doxorubicin | 1 | 1994 | 2234 | 0.000 |
Why?
|
Cell Cycle | 1 | 1996 | 2967 | 0.000 |
Why?
|
Risk Assessment | 1 | 2008 | 23338 | 0.000 |
Why?
|
Contrast Media | 1 | 1999 | 5300 | 0.000 |
Why?
|
Particle Accelerators | 1 | 1986 | 173 | 0.000 |
Why?
|
Thorax | 1 | 1987 | 547 | 0.000 |
Why?
|
Cyclophosphamide | 1 | 1987 | 2242 | 0.000 |
Why?
|
Quality of Life | 1 | 1982 | 12804 | 0.000 |
Why?
|
Gene Expression | 1 | 1991 | 7799 | 0.000 |
Why?
|
Hydrocortisone | 1 | 1986 | 1826 | 0.000 |
Why?
|
Models, Biological | 1 | 1994 | 9583 | 0.000 |
Why?
|
RNA, Messenger | 1 | 1991 | 13033 | 0.000 |
Why?
|
Mice | 1 | 2002 | 81183 | 0.000 |
Why?
|
Adolescent | 1 | 1994 | 85781 | 0.000 |
Why?
|
Brain | 1 | 1987 | 26385 | 0.000 |
Why?
|